An Open-label, Multi-center, Dose-escalation and Cohort Expansion Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Efficacy of ACR246 in Patients With Advanced Solid Tumors
NCT ID: NCT06238401
Last Updated: 2025-11-24
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
77 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-10-29
Study Completion Date
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of the study is to evaluate the safety and tolerability of ACR246 in patients with advanced solid tumors, to determine the maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of ACR246.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
NCT07231211
Solid Tumors
RECRUITING
PHASE1/PHASE2
A Study of AK-1286 in Patients With Advanced Solid Tumors
NCT06779045
Advanced Solid Tumor
NOT_YET_RECRUITING
PHASE1
A Study of HS248 in Patients With Advanced Solid Tumors
NCT05759234
Solid Tumor, Adult
UNKNOWN
PHASE1
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NCT05868876
Advanced Malignant Tumors
RECRUITING
PHASE1
A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer
NCT04311034
Non Small Cell Lung Cancer
COMPLETED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Advanced Solid Tumors
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ACR246 for injection
Administered by intravenous infusion on Day 1 every 3 weeks (Q3W).
Group Type
EXPERIMENTAL
ACR246 for injection
Intervention Type
DRUG
80 mg/vial
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ACR246 for injection
80 mg/vial
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be willing to sign the ICF, be able to understand the study, and be willing to follow and be able to complete all the study procedures;
2. Male and female, aged 18 to 75 years (inclusive);
3. For phase I dose escalation study: Patients with histologically or cytologically confirmed recurrent or metastatic unresectable advanced solid tumors who experience disease progression after receiving systemic standard therapy, or have no standard therapy;
4. For phase IIa cohort escalation study: Patients with histologically or cytologically confirmed recurrent or metastatic unresectable advanced solid tumors who experience disease progression after receiving systemic standard therapy, or have no standard therapy, including the following malignant tumors:
1. Esophageal cancer: Patients who experience disease progression after receiving prior ≥2 lines of chemotherapy;
2. Colorectal cancer: Patients who experience disease progression after receiving prior ≥2 lines of chemotherapy;
3. NSCLC: Patients with NSCLC meet the following conditions, and are unable to continue subsequent standard of care or have no standard of care available as judged by the investigator:
i. Positive for driver genes (such as EGFR, ALK, ROS1, MET); disease progression after current standard targeted therapy; ii. Negative for driver genes (such as EGFR, ALK, ROS1, MET); disease progression after prior ≥1 line(s) of therapy, and use of platinum-based drugs in at least one regimen; d) Ovarian cancer: Patients who experience disease progression after receiving at least one prior line of chemotherapy; the patient must receive prior treatment with PARP inhibitors if harboring BRCA 1/2 mutations; e) Prostate cancer: Patients with metastatic castration-resistant prostate cancer who receive at least one prior systemic therapy; f) Other solid tumors: Patients who experience disease progression after receiving prior standard of care, have no standard of care available, or are currently unsuitable to receive standard of care.
5. Positive for 5T4 expression as detected by the central laboratory (phase IIa only);
6. Phase I: Presence of at least one evaluable lesion by imaging as per RECIST v1.1; phase IIa: Presence of at least one measurable lesion by imaging as per RECIST v1.1. Lesions that are previously treated with radiotherapy cannot be considered target lesions unless the lesions have unequivocal progression;
7. Toxicity from prior antitumor therapies returned to Grade ≤1 as defined by NCI-CTCAE v5.0, but with the exception for alopecia- or antitumor therapy-associated events that can be tolerated by patients as judged by the investigator;
8. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1;
9. Adequate bone marrow, liver, kidney, and coagulation functions (refer to the upper limit of normal \[ULN\] of each clinical study site):
Bone marrow (did not receive blood transfusion or use drugs that increase white blood cells and platelets, e.g., cytokines or erythropoietin, within 2 weeks prior to laboratory tests):
Absolute neutrophil count (ANC) count ≥1.5×109/L; Platelet (PLT) ≥100×109/L; Haemoglobin (Hb) ≥90 g/L;
Liver function:
Total bilirubin (TBiL) ≤1.5 × ULN; ALT, AST ≤2.5 × ULN in patients without metastases to liver; ALT, AST ≤5 × ULN in patients with metastases to liver;
Kidney function:
Creatinine ≤1.5 × ULN or creatinine clearance (Ccr) ≥60 mL/min (according to the Cockcroft-Gault formula);
Coagulation function:
International normalized ratio (INR) ≤1.5 × ULN; Activated partial thromboplastin time (APTT) ≤1.5 × ULN;
10. Expected survival ≥3 months;
11. At rest, left ventricular ejection fraction (LVEF) ≥50%;
12. Eligible male patients of reproductive potential and female patients of childbearing potential, along with his/her partner, must agree to use medically acceptable contraceptive measures (e.g., hormonal contraception, barrier method, or abstinence, etc.) during the study and for at least 6 months after the last dose.
2. Male and female, aged 18 to 75 years (inclusive);
3. For phase I dose escalation study: Patients with histologically or cytologically confirmed recurrent or metastatic unresectable advanced solid tumors who experience disease progression after receiving systemic standard therapy, or have no standard therapy;
4. For phase IIa cohort escalation study: Patients with histologically or cytologically confirmed recurrent or metastatic unresectable advanced solid tumors who experience disease progression after receiving systemic standard therapy, or have no standard therapy, including the following malignant tumors:
1. Esophageal cancer: Patients who experience disease progression after receiving prior ≥2 lines of chemotherapy;
2. Colorectal cancer: Patients who experience disease progression after receiving prior ≥2 lines of chemotherapy;
3. NSCLC: Patients with NSCLC meet the following conditions, and are unable to continue subsequent standard of care or have no standard of care available as judged by the investigator:
i. Positive for driver genes (such as EGFR, ALK, ROS1, MET); disease progression after current standard targeted therapy; ii. Negative for driver genes (such as EGFR, ALK, ROS1, MET); disease progression after prior ≥1 line(s) of therapy, and use of platinum-based drugs in at least one regimen; d) Ovarian cancer: Patients who experience disease progression after receiving at least one prior line of chemotherapy; the patient must receive prior treatment with PARP inhibitors if harboring BRCA 1/2 mutations; e) Prostate cancer: Patients with metastatic castration-resistant prostate cancer who receive at least one prior systemic therapy; f) Other solid tumors: Patients who experience disease progression after receiving prior standard of care, have no standard of care available, or are currently unsuitable to receive standard of care.
5. Positive for 5T4 expression as detected by the central laboratory (phase IIa only);
6. Phase I: Presence of at least one evaluable lesion by imaging as per RECIST v1.1; phase IIa: Presence of at least one measurable lesion by imaging as per RECIST v1.1. Lesions that are previously treated with radiotherapy cannot be considered target lesions unless the lesions have unequivocal progression;
7. Toxicity from prior antitumor therapies returned to Grade ≤1 as defined by NCI-CTCAE v5.0, but with the exception for alopecia- or antitumor therapy-associated events that can be tolerated by patients as judged by the investigator;
8. Eastern Cooperative Oncology Group (ECOG) performance status score of ≤1;
9. Adequate bone marrow, liver, kidney, and coagulation functions (refer to the upper limit of normal \[ULN\] of each clinical study site):
Bone marrow (did not receive blood transfusion or use drugs that increase white blood cells and platelets, e.g., cytokines or erythropoietin, within 2 weeks prior to laboratory tests):
Absolute neutrophil count (ANC) count ≥1.5×109/L; Platelet (PLT) ≥100×109/L; Haemoglobin (Hb) ≥90 g/L;
Liver function:
Total bilirubin (TBiL) ≤1.5 × ULN; ALT, AST ≤2.5 × ULN in patients without metastases to liver; ALT, AST ≤5 × ULN in patients with metastases to liver;
Kidney function:
Creatinine ≤1.5 × ULN or creatinine clearance (Ccr) ≥60 mL/min (according to the Cockcroft-Gault formula);
Coagulation function:
International normalized ratio (INR) ≤1.5 × ULN; Activated partial thromboplastin time (APTT) ≤1.5 × ULN;
10. Expected survival ≥3 months;
11. At rest, left ventricular ejection fraction (LVEF) ≥50%;
12. Eligible male patients of reproductive potential and female patients of childbearing potential, along with his/her partner, must agree to use medically acceptable contraceptive measures (e.g., hormonal contraception, barrier method, or abstinence, etc.) during the study and for at least 6 months after the last dose.
Exclusion Criteria
Patients meeting any of the following criteria should be excluded from the study:
1. Comorbid with other primary malignant tumors, except for:
1. Resolved non-invasive basal cell carcinoma or squamous cell carcinoma, and cervical carcinoma in situ;
2. Or other malignant tumors with a more than 5-year disease free survival;
3. Malignant tumors other than those with a more than 5-year disease free survival, but the patient may obtain benefits after enrollment as he/she has a stable condition assessed by the investigator (for phase I dose escalation study only);
2. Received any systemic antitumor therapies (including chemotherapy, radiotherapy, biological therapy, immunotherapy, etc.) within 4 weeks prior to the first dose of the investigational drug; Received small molecule targeted drugs, Chinese herbal medicines or Chinese patent medicines with antitumor indications or systemic immunomodulators (including but not limited to interferon, interleukin-2, and tumor necrosis factor) within 2 weeks prior to the first dose of the investigational drug;
3. Prior treatment with any 5T4-targeted drug therapy;
4. Presence of active brain metastases or spinal cord metastases, being ineligible for inclusion in the study as assessed by the investigator; however, patients who require no radiotherapy, surgery or treatment with corticosteroids to control the symptoms of metastases within 1 month prior to screening may be included in the study; patients with metastases to meninges will be excluded;
5. Known hypersensitivity to any of the active ingredients or excipients of ACR246, or documented history of allergy to protein drugs, experienced other serious allergic reactions, for which, the patient is not suitable to receive ACR246 as assessed by the investigator;
6. History of severe heart disease as assessed by the investigator, e.g., symptomatic cardiac failure congestive (CHF) \[Class ≥2 as per New York Heart Association (NYHA) functional classification\], and history of myocardial infarction or unstable angina pectoris within 6 months prior to screening;
7. Serious arrhythmia requiring medication, e.g., corrected QT interval (Frederica formula) \>450 msec for male or \>470 msec for female, complete left bundle branch block, third-degree atrioventricular block;
8. Uncontrolled hypertension after medication treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
9. Dyspnoea at rest, severe primary pulmonary disorder currently requiring continuous oxygen therapy, history of interstitial lung disease and radiation pneumonitis, uncontrolled or potential risk of pulmonary fibrosis, or clinically active lung diseases as indicated by any proof;
10. Serious or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, heart, liver or kidney diseases), as assessed by the investigator;
11. Positive antibody tests for active hepatitis B (hepatitis B surface antigen positive and HBV DNA≥1×103 IU/mL), active hepatitis C (hepatitis C antibody positive and HCV RNA \> lower limit of detection), active syphilis (treponema pallidum antibody positive and Rapid Plasma Reagin (RPR) titer positive), and human immunodeficiency virus (HIV) antibody positive, or any uncontrolled infections;
12. Had a major surgery or serious traumatic injuries (without complete recovery as assessed by the investigator) within 4 weeks prior to the first dose of the investigational drug, or plans to undergo a major surgery during the study;
13. Pregnant or lactating women;
14. Serious arterial/venous thrombosis (e.g., cerebrovascular accident \[including transient ischaemic attack\]), deep venous thrombosis, pulmonary embolism within 1 year prior to treatment with the investigational drug, or haemorrhagic diathesis within 30 days prior to enrollment, or existence of risks of massive gastrointestinal hemorrhage, as assessed by the investigator;
15. Use of strong cytochrome P450 3A enzymes (CYP450 3A) inhibitors or inducers could not be stopped during treatment with the investigational drug;
16. Active eye disorders, such as keratitis, corneal disorder or eye infection, requiring intervention (including surgery or drug therapy, etc.);
17. Other condition that in the opinion of the investigator is not suitable for the study, e.g., poor compliance.
1. Comorbid with other primary malignant tumors, except for:
1. Resolved non-invasive basal cell carcinoma or squamous cell carcinoma, and cervical carcinoma in situ;
2. Or other malignant tumors with a more than 5-year disease free survival;
3. Malignant tumors other than those with a more than 5-year disease free survival, but the patient may obtain benefits after enrollment as he/she has a stable condition assessed by the investigator (for phase I dose escalation study only);
2. Received any systemic antitumor therapies (including chemotherapy, radiotherapy, biological therapy, immunotherapy, etc.) within 4 weeks prior to the first dose of the investigational drug; Received small molecule targeted drugs, Chinese herbal medicines or Chinese patent medicines with antitumor indications or systemic immunomodulators (including but not limited to interferon, interleukin-2, and tumor necrosis factor) within 2 weeks prior to the first dose of the investigational drug;
3. Prior treatment with any 5T4-targeted drug therapy;
4. Presence of active brain metastases or spinal cord metastases, being ineligible for inclusion in the study as assessed by the investigator; however, patients who require no radiotherapy, surgery or treatment with corticosteroids to control the symptoms of metastases within 1 month prior to screening may be included in the study; patients with metastases to meninges will be excluded;
5. Known hypersensitivity to any of the active ingredients or excipients of ACR246, or documented history of allergy to protein drugs, experienced other serious allergic reactions, for which, the patient is not suitable to receive ACR246 as assessed by the investigator;
6. History of severe heart disease as assessed by the investigator, e.g., symptomatic cardiac failure congestive (CHF) \[Class ≥2 as per New York Heart Association (NYHA) functional classification\], and history of myocardial infarction or unstable angina pectoris within 6 months prior to screening;
7. Serious arrhythmia requiring medication, e.g., corrected QT interval (Frederica formula) \>450 msec for male or \>470 msec for female, complete left bundle branch block, third-degree atrioventricular block;
8. Uncontrolled hypertension after medication treatment (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg);
9. Dyspnoea at rest, severe primary pulmonary disorder currently requiring continuous oxygen therapy, history of interstitial lung disease and radiation pneumonitis, uncontrolled or potential risk of pulmonary fibrosis, or clinically active lung diseases as indicated by any proof;
10. Serious or uncontrolled systemic diseases (e.g., unstable or uncompensated respiratory, heart, liver or kidney diseases), as assessed by the investigator;
11. Positive antibody tests for active hepatitis B (hepatitis B surface antigen positive and HBV DNA≥1×103 IU/mL), active hepatitis C (hepatitis C antibody positive and HCV RNA \> lower limit of detection), active syphilis (treponema pallidum antibody positive and Rapid Plasma Reagin (RPR) titer positive), and human immunodeficiency virus (HIV) antibody positive, or any uncontrolled infections;
12. Had a major surgery or serious traumatic injuries (without complete recovery as assessed by the investigator) within 4 weeks prior to the first dose of the investigational drug, or plans to undergo a major surgery during the study;
13. Pregnant or lactating women;
14. Serious arterial/venous thrombosis (e.g., cerebrovascular accident \[including transient ischaemic attack\]), deep venous thrombosis, pulmonary embolism within 1 year prior to treatment with the investigational drug, or haemorrhagic diathesis within 30 days prior to enrollment, or existence of risks of massive gastrointestinal hemorrhage, as assessed by the investigator;
15. Use of strong cytochrome P450 3A enzymes (CYP450 3A) inhibitors or inducers could not be stopped during treatment with the investigational drug;
16. Active eye disorders, such as keratitis, corneal disorder or eye infection, requiring intervention (including surgery or drug therapy, etc.);
17. Other condition that in the opinion of the investigator is not suitable for the study, e.g., poor compliance.
Minimum Eligible Age
18 Years
Maximum Eligible Age
75 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hangzhou Adcoris Biopharmacy Co., Ltd
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Site Status
RECRUITING
Beijing Tumor Hospital
Beijing, Beijing Municipality, China
Site Status
RECRUITING
Zhejiang Cancer Hospital
Zhejiang, Hangzhou, China
Site Status
RECRUITING
Shandong First Medical University affiliated Cancer Hospital of Shandong
Shandong, Jinan, China
Site Status
RECRUITING
ShangHai Chest Hospital
Shanghai, Shanghai Municipality, China
Site Status
RECRUITING
ShangHai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ACR246-101
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors
NCT05142423
RECRUITING
PHASE1/PHASE2
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820
RECRUITING
PHASE1/PHASE2
A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
NCT04264936
UNKNOWN
PHASE1/PHASE2
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
NCT05235542
UNKNOWN
PHASE1/PHASE2
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
NCT06424665
RECRUITING
PHASE1
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
NCT07102004
RECRUITING
PHASE1/PHASE2
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
NCT07229612
NOT_YET_RECRUITING
PHASE1/PHASE2
A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
NCT06166472
NOT_YET_RECRUITING
PHASE1
SKB445 for Injection in Solid Tumors
NCT06826040
RECRUITING
PHASE1
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors
NCT07136142
NOT_YET_RECRUITING
PHASE1/PHASE2
A Phase I Study on ReT01 ACT for the Treatment of Advanced Solid Tumors
NCT06257680
RECRUITING
PHASE1
Exploratory Clinical Study of Personalized mRNA Tumor Vaccine RH125 in Patients With Advanced Solid Tumors
NCT07182435
NOT_YET_RECRUITING
EARLY_PHASE1
A Study of AK129 in Patients With Advanced Malignant Tumors
NCT05645276
RECRUITING
PHASE1
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
NCT06840821
RECRUITING
PHASE1/PHASE2
A Study of AK146D1 for Injection in Advanced Solid Tumors
NCT07067567
RECRUITING
PHASE1
A Study of MRG003 in Patients With Advanced Solid Tumors
NCT04868344
COMPLETED
PHASE1
A Phase I Study of NK042 Cell Injection in Advanced Solid Tumors
NCT06773091
RECRUITING
PHASE1
A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors
NCT06520488
RECRUITING
PHASE1/PHASE2
A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours
NCT06027346
RECRUITING
PHASE1
A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors
NCT04908046
COMPLETED
PHASE1
A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors
NCT04172506
COMPLETED
PHASE1/PHASE2
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
NCT06231550
COMPLETED
PHASE1
A Phase II Study of SHR-4602 as Montherapy or in Combination With Other Anti-tumor Therapies in Advanced Solid Tumors
NCT06704828
NOT_YET_RECRUITING
PHASE2
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
NCT06947226
NOT_YET_RECRUITING
PHASE1/PHASE2
An Phase I Study of YY001 in Patients with Advanced Solid Tumors
NCT06228846
COMPLETED
PHASE1